We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. announced the launch of ABILIFY DISCMELT (aripiprazole) Orally Disintegrating Tablets, a new oral form of the antipsychotic medication ABILIFY (aripiprazole) that disintegrates rapidly in the mouth.
Pennsylvania environmental regulators have accused Merck of hampering their investigation of a chemical discharge from its West Point facility that resulted in a major fish kill on the local creek and threatened the water supplies for the city of Philadelphia.
A federal appeals court upheld a ban on products containing the weight loss supplement ephedra, reversing a Utah judge who stopped enforcement of the prohibition against Park City-based Nutraceutical Corp.
Pfizer Inc said that a federal court jury in the Eastern District of Virginia (Alexandria) has ruled unanimously that Pfizer does not infringe Synthon IP's U.S. patent covering a process for making amlodipine, the active ingredient in Norvasc.
Apotex Inc., the generic-drug company that is selling a low-cost version of the blood thinner Plavix, admitted in court papers that it struck a "side agreement" with Bristol-Myers Squibb Co. and Sanofi-Aventis.
Barr Pharmaceuticals Inc. has refiled its application to sell the Plan B "morning-after" pill without a prescription, a Food and Drug Administration spokeswoman said on Friday.
Croatian regulators have approved the publication in the country's major national newspapers of Barr Laboratories' offer for Croatian generic drug firm Pliva, permitting the company to announce terms of the bid to Pliva shareholders, Barr announced.
The FDA has issued a not approvable letter for Cephalon's attention-deficit/hyperactivity disorder (ADHD) drug Sparlon, leading the company to announce it will stop developing the drug altogether.